Name: URGN Income Statement - Urogen Pharma Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

URGN - Urogen Pharma Ltd.

USD | NASDAQ | Healthcare

URGN Income Statement - Urogen Pharma Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17
Revenues
Revenues	51.0	37.8	27.5	24.2	20.3	24.6	25.2	21.8	18.8	23.5	20.9	21.1	17.2	18.1	16.1	16.6

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Revenues
Revenues	140.5	109.8	90.4	82.7	64.4	48.0	11.8	0.0	1.1	8.2	17.5	-
Cost of Revenue	14.3	12.4	8.9	9.4	7.7	5.2	1.0	-	1.8	0.6	0.0	-
Gross Profit	126.2	97.3	81.5	73.4	56.7	42.9	10.8	-	(0.7)	7.6	17.5	-
Operating Expenses
Research & Development	62.8	67.1	57.1	45.6	52.9	47.6	47.3	49.3	36.9	18.7	-	-
Selling General & Administrative	171.6
Operating Income
Operating Income	(108.2)	(124.9)	(96.8)	(65.5)	(79.0)	(92.3)	(126.7)	(109.5)	(77.2)	(20.0)	0.8	(12.4)
Non-Operating
Interest Income	4.7	6.0	8.9	2.6	0.9	0.4	2.0	4.6	-	-	-	-
Interest Expense	-	-
Tax & Net
Income Tax Expense	(5.1)	0.1	2.8	3.9	1.8	1.4	3.4	-	0.1	0.0	-	-
Net Income From Continuing Ops	(133.2)
Per Share
EPS Basic	(2.65)	(3.19)	(2.96)	(3.55)	(4.81)	(4.96)	-	-	-	-	-	-
EPS Diluted	-	-
Supplementary Data
EBITDA	(107.9)	(124.6)	(96.5)	(64.7)	(78.1)	(91.5)	(126.3)	(109.2)	(76.8)	(19.8)	1.0	(12.3)
EBIT	(108.2)	(124.9)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	15.6	14.3	14.0	18.9	19.9	14.9	11.4	15.4	15.5	11.3	10.2	11.6	12.5	14.5	13.1	12.6	12.7	13.1	11.9	12.1	10.5	12.4	10.2	8.1	16.6	20.1	9.5	10.0	9.7	11.5	9.6	8.3	7.6	6.8	5.6	3.7	2.7
Selling General & Administrative	51.5	39.3	37.6	43.2	35.0	34.9	28.9	30.1	27.3	24.6	21.8	22.5	24.5	21.6	19.1	20.8
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.3	0.2	0.2
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Operating Income
Operating Income	(20.3)	(19.1)	(27.4)	(41.4)	(36.9)	(27.7)	(17.5)	(25.8)	(25.7)	(14.6)	(13.5)	(15.4)	(22.0)	(20.3)	(18.1)	(18.7)	(22.0)	(19.9)	(23.4)	(22.8)	(26.1)	(27.3)	(29.1)	(31.8)	(38.6)	(39.8)	(23.5)	(23.8)	(22.4)	(24.0)	(21.1)	(18.4)	(13.6)	(10.2)	(0.3)	(6.0)	(3.5)

Non-Operating
Interest Income	0.9	0.9	1.2	1.7	2.2	2.8	2.8	1.5	1.8	0.7	0.8	0.4	0.6	-	0.4	-	0.0	-	-	-	0.2	-	-	-	0.8	-	-	-	1.0	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Income	(0.3)	(0.0)	(0.2)	(0.4)	(0.1)	(0.1)	(0.2)	0.2	(0.2)	0.8	0.1	(0.0)	(0.0)	-	0.0	-	(0.0)
Pre-Tax Income	(28.3)	(26.6)	(34.4)	(48.9)	(43.5)	(34.9)	(23.6)	(33.4)	(32.2)	(22.2)	(21.9)	(24.1)	(30.2)	(28.2)	(25.1)	(26.7)

Tax & Net
Income Tax Expense	(4.8)	(0.3)	(1.1)	1.0	0.4	2.6	0.1	0.0	0.1	3.9	(0.0)	0.1	0.0	0.7	0.7	0.0	0.3	1.1	0.0	0.3	0.0	-	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	(23.6)	(26.4)	(33.3)	(49.9)	(43.8)	(37.5)	(23.7)	(33.4)	(32.3)	(26.0)	(21.9)	(24.1)	(30.2)	(28.9)	(25.8)	(26.7)	(28.4)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(23.6)	(26.4)	(33.3)	(49.9)	(43.8)	(37.5)	(23.7)	(33.4)	(32.3)	(26.0)	(21.9)	(24.1)	(30.2)	(28.9)	(25.8)	(26.7)	(28.4)
Net Income Attributable To Parent	(23.6)	(26.4)	(33.3)	(49.9)	(43.8)	(37.5)	(23.7)	(33.4)	(32.3)	(26.0)	(21.9)	(24.1)	(30.2)	(28.9)	(25.8)	(26.7)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(23.6)	(26.4)	(33.3)	(49.9)	(43.8)	(37.5)	(23.7)	(33.4)	(32.3)	(26.0)	(21.9)	(24.1)	(30.2)	(28.9)	(25.8)

Per Share
EPS Basic	(0.47)	-	(0.69)	(1.05)	(0.92)	-	(0.51)	(0.82)	(0.87)	-	(0.68)	(1.03)	(1.30)	-	(1.13)	(1.18)	(1.25)	-	(1.35)	(1.17)	(1.17)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Diluted	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Basic	50.2	-	48.1	47.7	47.4	-	46.8	40.5	37.1	-	32.3	23.5	23.3	-	22.8	22.7	22.6	-
Shares Diluted	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Supplementary Data
EBITDA	(20.2)	(19.1)	(27.3)	(41.3)	(36.8)	(27.7)	(17.4)	(25.7)	(25.6)	(14.4)	(13.3)	(15.2)	(21.8)	(20.0)	(17.9)	(18.5)	(21.7)	(19.7)	(23.2)	(22.6)	(25.9)	(27.1)	(29.0)	(31.7)	(38.5)	(39.8)	(23.4)	(23.7)	(22.3)	(24.0)	(21.0)	(18.4)	(13.4)	-	-	-	-
EBIT	(20.3)	(19.1)	(27.4)	(41.4)	(36.9)	(27.7)	(17.5)	(25.8)	(25.7)	(14.6)	(13.5)	(15.4)	(22.0)	(20.3)	(18.1)	(18.7)	(22.0)	(19.9)	(23.4)